Innoviva, Inc. (NASDAQ:INVA) Shares Bought by Pacer Advisors Inc.

Pacer Advisors Inc. boosted its holdings in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,932,113 shares of the biotechnology company's stock after buying an additional 121,162 shares during the period. Pacer Advisors Inc. owned approximately 4.68% of Innoviva worth $50,872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of Innoviva by 254.2% during the third quarter. Barclays PLC now owns 100,594 shares of the biotechnology company's stock valued at $1,942,000 after acquiring an additional 72,192 shares in the last quarter. Jane Street Group LLC grew its position in Innoviva by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 136,361 shares of the biotechnology company's stock worth $2,633,000 after purchasing an additional 43,218 shares during the last quarter. FMR LLC increased its stake in Innoviva by 8.2% during the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 771 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of Innoviva in the third quarter worth $715,000. Finally, Victory Capital Management Inc. lifted its stake in shares of Innoviva by 3.5% during the third quarter. Victory Capital Management Inc. now owns 140,454 shares of the biotechnology company's stock worth $2,712,000 after buying an additional 4,699 shares during the period. 99.12% of the stock is currently owned by hedge funds and other institutional investors.

Innoviva Stock Performance

Shares of INVA stock traded down $0.29 on Friday, hitting $18.61. The company had a trading volume of 320,367 shares, compared to its average volume of 582,211. The firm has a market cap of $1.16 billion, a P/E ratio of 26.97 and a beta of 0.54. Innoviva, Inc. has a twelve month low of $14.32 and a twelve month high of $21.28. The company has a 50-day moving average price of $18.31 and a 200-day moving average price of $18.84. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38.

Innoviva (NASDAQ:INVA - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.27 by ($0.25). The company had revenue of $89.51 million during the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. As a group, equities research analysts predict that Innoviva, Inc. will post 0.33 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Innoviva from a "buy" rating to a "hold" rating in a research note on Tuesday, December 31st.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.